X4 Pharmaceuticals, Inc. Common Stock
XFORX4 Pharmaceuticals, Inc. (XFOR) is a biopharmaceutical company focused on developing therapies for rare diseases, particularly immune-mediated and hematologic disorders. The company's approach involves targeting mechanisms of immune regulation to address unmet medical needs in underserved patient populations.
Company News
X4 Pharmaceuticals announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of mavorixafor (XOLREMDI) for treating WHIM syndrome in the EU. The drug, already FDA-approved in the U.S., would be the first and only therapy available in Europe for this ul...
X4 Pharmaceuticals announced a public offering of 45,860,000 shares and pre-funded warrants, expecting to raise approximately $135 million to fund Phase 3 development of mavorixafor for chronic neutropenic disorders.
Sitryx Therapeutics has appointed Adam Mostafa as its new Chief Financial Officer, bringing over 25 years of biotech financial experience, including previous roles at X4 Pharmaceuticals and Abpro Holdings.
X4 Pharmaceuticals secured a $60 million PIPE financing led by Coastlands Capital, with significant management and board leadership changes, including new appointments of Dr. Adam Craig as Executive Chairman, John Volpone as President, and David Kirske as CFO.
X4 Pharmaceuticals announced positive results from a six-month Phase 2 trial of its drug mavorixafor in treating chronic neutropenia. The drug durably increased participants' mean absolute neutrophil counts and enabled substantial reductions in G-CSF dosing while maintaining normal ANC levels.
